Investment Opportunities
Absynth is seeking investment to fund key milestones to 2019. Absynth is also funded by private equity, corporate funding and business grants.
Information on how to invest is coming soon.
Absynth Biologics is led by experienced management, scientists and advisors, with strong track records.
Dr Fiona Marston, Chief Executive
Over 25 years experience in biotech and venture capital with a successful track record of strategic development, growth and management of companies.
Dr David Knowles, Chairman
With more than 20 years experience of antimicrobial research in major pharma companies, David was recently the scientific leader in two biotech businesses (Piramed & RiboTargets) that achieved successful exit for investors.
Professor Simon Foster Chief Scientific Officer
Leading expert on S. aureus with >20 years experience and currently has the largest academic laboratory working on this bacterium in the UK.
Mr Mark Hollingworth, Finance Director
Mark is life sciences Financial Director with broad experience within industry, previously at Astra Zeneca as Finance Director Discovery Science and Global Safety.
Dr Neill Gingles; Head of Research
Neill has worked for over 18 years within academia and the pharmaceutical industry. He has a proven track record of research as evidenced by publications in a variety of scientific and medical research areas predominantly infectious disease, oncology, cardiovascular disease, and drug safety assessment.
Expert advisers
Drs. Mike Darsley & Philip Bedford (ex-Acambis; vaccine clinical development); Dr Martin Comberbach (ex-SKB Biologicals; vaccine manufacture; Prof. Vance Fowler (clinician, S. aureus); Dr J Mond (ex-CSO Biosynexus, clinician, S. aureus); Prof Mark Wilcox (clinician, C. difficile).
Comments are closed.